The Indian pharmaceutical market has been growing at an annual compounded rate of 15% and is valued at Rs. 55,000 crores ($10 billion). This surge can be attributed to higher private healthcare spending by Indians, greater penetration of pharmaceutical companies into the country’s interior, and an increasing awareness of chronic issues like cardiac disease and diabetes. According to a report by consultancy group McKinsey, pharmaceutical growth in India will triple to Rs. 1,00,000 crores (US$20 billion) by 2015 when India will be one of the world’s top 10 pharmaceutical markets.

JBCPL is among the top 40 pharmaceutical companies in the local market and the top 20 pharmaceutical companies with India and exports business.

JBCPL has three divisions
JBCPL has a presence in 22 major therapeutic groups with 108 brands in the domestic market. Some of JBCPL’s leading brands in India are in Amoebicides, Anti-peptic ulcerants, NSAID, Cardiac care, Quinolones and Antacids. They are among the top 300 brands in terms of units in the Indian pharmaceutical market Some of these brands have achieved brand leadership in their segments Below are brands that are top ranking in therapeutic segments: In India we aim to:
DPCO 13 Form V Price List – click here for more